If the information does not match the information on the packaging, you can complete or correct it
The medication is indicated for adults with type 2 diabetes to improve glycemic control as an adjunct to diet and exercise, and for chronic weight management in adults with obesity (BMI 30 kg/m) or overweight (BMI 27 kg/m) with at least one weight-related comorbidity
A commitment to ongoing monitoring and follow-up to ensure the medication is effective and safe for the patient
GLP-1 receptor agonists do not
Muscle cramps during GLP-1 therapy are typically caused by indirect factors including electrolyte depletion (especially magnesium and potassium) from gastrointestinal side effects, dehydration from reduced fluid intake or vomiting/diarrhea, rapid weight loss with some lean mass reduction, and increased physical activity exceeding current conditioning levels
In addition, pathway analysis identified arachidonic acid, glutathione, and nicotinate/nicotinamide metabolism as among the most significantly affected pathways
